Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;170(1):101-109.
doi: 10.1007/s10549-018-4727-9. Epub 2018 Feb 22.

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

Katherine Clifton  1   2 , Angelica Gutierrez-Barrera  3 , Junsheng Ma  3 , Roland Bassett Jr  3 , Jennifer Litton  3 , Henry Kuerer  3 , Stacy Moulder  3 , Constance Albarracin  3 , Gabriel Hortobagyi  3 , Banu Arun  3
Affiliations

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

Katherine Clifton et al. Breast Cancer Res Treat. 2018 Jul.

Abstract

Purpose: As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is essential. Several retrospective studies in triple-negative breast cancer have reported conflicting results in overall survival in patients receiving neoadjuvant or adjuvant systemic therapy. This study aims to analyze outcomes of adjuvant versus neoadjuvant in patients with early-stage triple-negative breast cancer with and without BRCA germline mutations.

Methods: Patients with stage I or II triple-negative breast cancer who had BRCA testing were identified from a prospective cohort study of 4027 patients. Clinical, demographic, genetic test results, chemotherapy, recurrence, and survival data were analyzed. Overall survival and disease-free survival were estimated using the Kaplan-Meier method.

Results: 319 patients with stage I and II triple-negative breast cancer who met eligibility criteria were included in the analysis. 187 received adjuvant chemotherapy (58.6%) and 132 received neoadjuvant chemotherapy (41.4%). 135 were BRCA positive (42.3%) and 184 were BRCA negative (57.7%). There was no significant association between overall survival or disease-free survival and treatment with neoadjuvant versus adjuvant in the overall cohort. Furthermore, there were no significant differences between patient subgroups (neoadjuvant BRCA positive, neoadjuvant BRCA negative, adjuvant BRCA positive, and adjuvant BRCA negative) with respect to either overall survival or disease-free survival.

Conclusions: Neoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents.

Keywords: Adjuvant chemotherapy; BRCA mutation; Neoadjuvant chemotherapy; Triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The remaining authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier plot of overall survival for triple-negative breast cancer patients receiving adjuvant (N = 187) and neoadjuvant (N = 132), p value is 0.404
Fig. 2
Fig. 2
Kaplan–Meier plot of disease-free survival for triple-negative breast cancer patients receiving adjuvant (N = 187) and neoadjuvant (N = 132), p value is 0.735
Fig. 3
Fig. 3
Kaplan–Meier plot of overall survival for patient subgroups of neoadjuvant BRCA positive (N = 48), neoadjuvant BRCA negative (N = 84), adjuvant BRCA positive (N = 86), and adjuvant BRCA negative (N = 100), p value is 0.287
Fig. 4
Fig. 4
Kaplan–Meier plot of disease-free survival for patient subgroups of neoadjuvant BRCA positive (N = 48), neoadjuvant BRCA negative (N = 84), adjuvant BRCA positive (N = 87), and adjuvant BRCA negative (N = 100), p value is 0.731
See this image and copyright information in PMC

References

    1. American Cancer Society. [Accessed 4 Dec 2017];Cancer Facts & Figures 2017 Supplemental Data. 2017 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-....
    1. Stover D, Bell CF, Tolaney SM. Neoadjuvant and adjuvant chemotherapy considerations for triple negative breast cancer. Am J Hematol Oncol. 2016;12(3):6–12.
    1. Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–2795. - PubMed
    1. Meyer P, Landgraf K, Hogel B, et al. BRCA2 mutations and triple-negative breast cancer. [Accessed 26 Sept 2017];PLoS ONE. 2012 7(5):e38361. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038361. - PMC - PubMed
    1. Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707–714. - PMC - PubMed

MeSH terms

LinkOut - more resources